{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:52:32Z","timestamp":1776109952868,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xkme.2025.101198","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T07:49:55Z","timestamp":1765266595000},"page":"101198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study)"],"prefix":"10.1016","volume":"8","author":[{"given":"Ramy Magdy","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moh-Lim","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpita","family":"Nag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan A.","family":"Burdeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2025.101198_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina","year":"2019","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.xkme.2025.101198_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101198_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","article-title":"An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document","volume":"35","author":"Campistol","year":"2015","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.xkme.2025.101198_bib4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ekir.2022.02.021","article-title":"The rational use of complement inhibitors in kidney diseases","volume":"7","author":"Fakhouri","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.xkme.2025.101198_bib5","unstructured":"Soliris 300 mg concentrate for solution for infusion. Summary of product characteristics. European Medicines Agency. Accessed March 11, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/soliris-epar-product-information_en.pdf"},{"key":"10.1016\/j.xkme.2025.101198_bib6","unstructured":"Soliris prescribing information. US Food and Drug Administration. Accessed March 11, 2025. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/soliris_uspi.pdf"},{"key":"10.1016\/j.xkme.2025.101198_bib7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101198_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2025.101198_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xkme.2025.101198_bib10","unstructured":"ULTOMIRIS prescribing information. US Food and Drug Administration. Accessed September 24, 2024. https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2025\/english\/ultomiris_uspi.pdf?rev=7ab9a5262ccb4e56a42a560d3107082d"},{"key":"10.1016\/j.xkme.2025.101198_bib11","unstructured":"Ultomiris summary of product characteristics. European Medicines Agency. Accessed September 24, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf"},{"key":"10.1016\/j.xkme.2025.101198_bib12","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101198_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2025.101198_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00467-020-04774-2","article-title":"The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab","volume":"36","author":"Tanaka","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.xkme.2025.101198_bib15","article-title":"Pregnancy-associated atypical hemolytic uremic syndrome successfully treated with ravulizumab: a case report","volume":"16","author":"Miyazaki","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.xkme.2025.101198_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.1252","article-title":"#1028 Experience with ravulizumab in atypical hemolytic uremic syndrome","volume":"39","author":"Saiz","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2025.101198_bib17","article-title":"A case of carfilzomib-induced atypical hemolytic uremic syndrome","volume":"3","author":"Opare-Addo","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xkme.2025.101198_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/nep.70010","article-title":"A case of atypical hemolytic uremic syndrome with a complement factor I mutation triggered by a femoral neck fracture","volume":"30","author":"Kano","year":"2025","journal-title":"Nephrology"},{"key":"10.1016\/j.xkme.2025.101198_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000542788","article-title":"Atheroembolic kidney disease and atypical haemolytic uremic syndrome: two sides of the same coin?","volume":"50","author":"Pisani","year":"2025","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.xkme.2025.101198_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100683","article-title":"Atypical hemolytic uremic syndrome treated with ravulizumab or eculizumab: a CLAIMS-based evaluation of health care resource utilization and clinical outcomes in the United States","volume":"5","author":"Wang","year":"2023","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2025.101198_bib21","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ekir.2024.06.020","article-title":"Global aHUS registry analysis of patients switching to ravulizumab from eculizumab","volume":"9","author":"Schaefer","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.xkme.2025.101198_bib22","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1007\/s00467-021-05203-8","article-title":"Real-world data of six patients with atypical hemolytic uremic syndrome switched to ravulizumab","volume":"36","author":"Ehren","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.xkme.2025.101198_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12882-024-03638-3","article-title":"Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data","volume":"25","author":"Schonfelder","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.xkme.2025.101198_bib24","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0036","article-title":"Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome","volume":"12","author":"Mauch","year":"2023","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.xkme.2025.101198_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.xkme.2025.101198_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/nep.14304","article-title":"Characterization of patients with aHUS and associated triggers or clinical conditions: a global aHUS registry analysis","volume":"29","author":"Licht","year":"2024","journal-title":"Nephrology"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525002341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:29:59Z","timestamp":1773980999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525002341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2590059525002341"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101198","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study)","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101198","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101198"}}